We are the first to use targeted delivery methods to combat fibrosis - a condition that afflicts millions of people worldwide. Our approach towards fibrosis is not only about extending and saving lives, but also about improving quality of life for those suffering fibrotic disease. Many fibrosis patients are young; our aim is to give them the chance to lead a healthy, happy life.
Research points to long-term growth in a multitude of fibrotic illnesses.
In the US alone, almost five million people are living with chronic liver disease
Kidney fibrosis affects as many as 50 million people in the EU and USA alone
Other than transplant or the removal of the affected organs, there are no curative treatment options for advanced fibrosis
UK deaths due to liver disease have risen by 400% since 1970 (britishlivertrust.org.uk)
Modern Western lifestyle will cause a rise of fibrotic disease within years
Lung fibrosis may develop in more than half of severe COVID-19 patients
With an experienced, close-knit scientific team, we are ready to take our solution to the next level. We hold all required knowledge and expertise under one roof - LinXis’ specialists self-manage the entire pharmaceutical development cycle – from Fibrobody-drug conjugate design to preclinical- and clinical development.